This specificity positions ZK53 as a more suitable candidate for assessing the potential of ClpP as a targeted therapeutic strategy in cancer, thereby minimizing the off-target effects and inherent unpredictability associated with polypharmacological agents. Here, CLPP is linked to cancer.